An observational study in Influenza, Respiratory Virus and Coronavirus, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 186 studies in Influenza, Human by National Institute of Allergy and Infectious Diseases (NIAID) — 11 open to participants now, 12 under way, none of them phase 3. Influenza, Human · National Institute of Allergy and Infectious Diseases (NIAID).
Among the 186 studies in Influenza, Human by National Institute of Allergy and Infectious Diseases (NIAID), this one is the 5th largest by planned enrollment of the 20 observational ones that give a count, is one of 5 that started in 2023, is one of 20 observational ones, reaches primary completion later than 5 of the 10 other live ones, and was the 166th registered.
2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.
Browse Influenza, Human studies →11 of the 186 studies in Influenza, Human by National Institute of Allergy and Infectious Diseases (NIAID) are open now, in 1 country. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–55 · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–59 · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–55 · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–50 · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 3–17
By country, each count listing its studies:
Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
186 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 96 · Phase 2 67 · Phase 3 5 · Phase 4 11
First in 2000; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 403 across 335 observational studies indexed under Influenza, Human.
Median enrollment 83 across the 166 interventional studies, 190 across the 20 observational. Of the 165 that completed or were terminated, 53 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,449 studies on the registry; 181 are open to participants now.
Of its 406 completed or terminated interventional studies of FDA-regulated products, 303 (75%) have results posted.
9 of the studies in Influenza, Human by National Institute of Allergy and Infectious Diseases (NIAID) that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07110532National Institute of Allergy and Infectious Diseases (NIAID)pH1N1 Blinded Challenge Study | 2027-03-29 |
| NCT07703514National Institute of Allergy and Infectious Diseases (NIAID)Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates | 2027-04-12 |
| NCT07169318National Institute of Allergy and Infectious Diseases (NIAID)First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics | 2027-05-01 |
| NCT06863142National Institute of Allergy and Infectious Diseases (NIAID)Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults | 2027-05-10 |
| NCT02511002National Institute of Allergy and Infectious Diseases (NIAID)Long-term Observation of Hemagglutinin and Neuraminidase Inhibition Antibody Titers After Influenza Challenge | 2027-05-12 |
Add all 9 to your calendar (.ics) → With an account.
Among the 186 studies in Influenza, Human by National Institute of Allergy and Infectious Diseases (NIAID), from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background:
Respiratory viruses circulate throughout the year and around the globe. Wearable and sensor devices, like smartwatches, may be able to help monitor infectious diseases. Researchers want to use them to learn how respiratory viruses affect people in different ways.
Objective:
To use digital devices to collect data from participants in challenge studies that could indicate subtle changes in health during an infection that might otherwise go unnoticed.
Eligibility:
Healthy adults who have enrolled, were recently enrolled, or are scheduled to enroll in a challenge study.
Design:
Participants will stay at NIH for the duration of the challenge study (at least 9 days) and then will have outpatient follow-up visits (2-4).
While at NIH, participants will wear a smartwatch at all times. It will record data like temperature, heart rate, breathing rate, and movements.
Participants will have a smartphone that records at all times to listen for coughing and changes in voice.
Participants will perform tasks every 4 hours during the daytime. They will record themselves coughing, breathing in deeply, and reading aloud. They will take videos of their face. They will play a game to test their reflexes and focus. They will measure their head temperature with their smartwatch.
For outpatient visits, participants will use one smartphone and the smartwatch to complete the above tasks.
Participants will be sent a smartwatch to wear at home at night to collect additional healthy data.
Participation will last the duration of each challenge study, and may range from 10 weeks to 2 years.
Study Description:
Wearable and sensor digital devices have the potential to be important tools in infectious diseases surveillance. In this study, digital devices will be used to evaluate responses before and after respiratory virus challenge on a separate NIH protocol. Participants recently enrolled, currently enrolled, or planned for enrollment in a challenge study are eligible. Devices will be worn and/or used during the inpatient hospitalization and at outpatient follow-up visits. Participants may be sent smartwatches at home to collect additional baseline or healthy data. Devices may collect data on coughing, speech, heart rate, heart rhythm, sweating, and temperature to identify digital biomarkers associated with respiratory virus infection. The correlation between digital device measurement data and clinical data, particularly on cough, will be determined. We hypothesize that sensor-collected data will correlate with symptom severity obtained by clinician assessment and participant report. We also hypothesize that digital biomarkers can predict influenza infection and can be used to develop a predictive model.
Objectives:
Primary:
Exploratory:
Endpoints:
Primary:
Cough quantity:
-Continuous cough measurements
Infection
Defined as:
Using predictor variables such as:
Secondary: Vital signs:
Exploratory:
Correlations between digital biomarker data and biological biomarker data (e.g. antibody titers)
Healthy volunteers currently enrolled in a respiratory virus challenge study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this study:
1. Any condition that, in the opinion of the investigator, contraindicates participation in this study.
Co-enrollment guidelines: Participants must be co-enrolled, planned for co-enrollment, or recently enrolled in a challenge study. Co-enrollment in other studies is restricted but may take place after study staff notification and only with approval of the principal investigator or designee.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Current participation in a respiratory virus challenge study at the NIH CC
To correlate continuous cough sensor data to cough severity after challenge.To develop a predictive model for MMID and asymptomatic influenza infection using digital biomarkers.
Cough is a known symptom of respiratory virus infections and can be quantified by objective measurements.Data from smart devices may be able to discern who gets sick with a respiratory virus and could be utilized as a diagnostic tool.
Time frame: minimum of 9 days inpatient
To correlate continuous and noncontinuous vital signs sensor data to routine vital signs obtained by clinical staff.
Vital signs are routinely measured in challenge studies and are also routinely collected from digital devices. Vital sign changes can be associated with respiratory virus infections.
Time frame: minimum of 9 days inpatient
Started Oct 2023 (actual). Primary completion is estimated for Jun 2027, 43 months after the start.
Of 98 non-industry observational studies under Influenza, Human, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 92. This study's planned 43 months is above that.
Counting every sponsor, half of 135 studies reached it within 23 months; a quarter within 7 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institute of Allergy and Infectious Diseases (NIAID) →